DNTH
Healthcare BiotechnologyDianthus Therapeutics, Inc.
$88.21
-0.69 -0.78% today
Price History
Not enough data
Key Stats
Market Cap
4.82B
Avg Volume
820,034
EPS
-$4.24
52W High
$117.88
52W Low
$32.22
Div. Yield
0.0%
Analyst Ratings
Buy1
Str Buy
15
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-19.13
P/B Ratio
4.12
P/S Ratio
2532.62
EV/EBITDA
-18.59
EV/Revenue
2126.28
Margins
Gross Margin 100.0%
Operating Margin (8079.1%)
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Revenue Growth (YoY)
294.3%
Return on Equity
(26.1%)
Return on Assets
(17.7%)
Liquidity & Leverage
Current Ratio
26.10
Quick Ratio
25.79
Debt / Equity
0.00
Total Cash
886.81M
Total Debt
1.29M
About
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
dianthustx.com